Genetics startup 23andMe said on Friday it is one step closer to resuming sales of its full-fledged health product, with the U.S. Food and Drug Administration accepting its first health report for review. The home genetics company said in a blog post that the FDA will begin evaluating the company's submission for a 510(k) application, a regulatory process that applies to most medical devices ...
This news brief sponsored by: MLM Software Central, a division of Inspetta: MLMSoftwareCentral.com
MLMSoftwareCentral.com is a resource for individuals starting an MLM or Direct Selling Business and provides leading MLM Software. A web-property of Inspetta LLC, providing innovative web, software and marketing services to business.
Call 888-221-0106 for more information.